Arrowhead Pharmaceuticals, Inc.
ARWR
$16.97
-$0.70-3.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.27% | -55.49% | -65.91% | -357.42% | -221.51% |
| Total Depreciation and Amortization | 22.80% | 30.22% | 45.97% | 69.54% | 58.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.13% | -3.68% | 12.93% | 4.74% | -3.60% |
| Change in Net Operating Assets | 31.57% | -86.47% | -55.93% | 103.15% | 81.67% |
| Cash from Operations | -24.13% | -429.26% | -455.51% | -191.68% | -56.05% |
| Capital Expenditure | 89.05% | 61.99% | 69.00% | -24.75% | -76.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.76% | -310.38% | -41.69% | -2,583.83% | 419.50% |
| Cash from Investing | 18.62% | -830.68% | 170.16% | -645.70% | 180.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 137.45% | -72.84% | -65.93% | 82,741.73% | -53.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7,628.09% | 47,292.08% | 4,335.48% | 82,741.73% | -99.89% |
| Foreign Exchange rate Adjustments | -217.24% | 2,733.99% | -182.28% | 135.14% | 147.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.37% | 498.99% | -96.81% | 203.27% | -155.89% |
